← All trials
NCT05046327
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2021
- Primary completion
- Apr 6, 2024
- Completion date
- Feb 19, 2025
- First posted
- Sep 16, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- —
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dova PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.